Too much alcohol, different gene surface? Alcohol abuse could be associated with monoamine oxidase A gene methylation by Tamm, Andres
University of Tartu 
Institute of Psychology 
 
 
 
 
Andres Tamm 
 
TOO MUCH ALCOHOL, DIFFERENT GENE SURFACE?  
Alcohol abuse could be associated with monoamine oxidase A gene methylation 
 
Research project 
 
 
Advisor: Jaanus Harro, MD, PhD 
Running head: MAOA methylation and alcohol abuse 
 
 
 
 
 
Tartu 2014  
TAMM 
2 
 
 
Too much alcohol, different gene surface? Alcohol abuse could be associated with monoamine 
oxidase A gene methylation 
Monoamine oxidase A (MAO-A) is an enzyme that metabolizes neurotransmitters involved in alcohol 
dependency. To investigate if MAO-A is associated with alcohol abuse, I compared MAOA gene methylation 
in males with or without alcohol use disorders (N = 24 and N = 55, respectively). Methylation of MAOA gene 
in white blood cells was used as an index of MAO-A activity in the brain. Average methylation was higher 
in males with alcohol use disorders (AUD), but only in the nonsmokers’ subsample (Wilcoxon p = 0.01, 
proportion of better responses = 0.86). Methylation at gene site CpG10 was also higher in nonsmokers with 
AUD (p = 0.05, proportion = 0.80). Interaction between smoking and methylation is a novel finding. Because 
the sample of nonsmokers is small (N = 5 + 19), these results should be considered only as initial. 
Keywords: monoamine oxidase A, DNA methylation, alcohol use disorder 
 
Liigne alkohol – muutused geeni pealispinnas? Alkoholi väärkasutamine võib olla seotud 
monoamiinoksüdaas A geeni metüleeritusega 
Monoamiinoksüdaas A (MAO-A) on ensüüm, mis lagundab alkoholsõltuvusega seotud virgatsaineid. 
Uurimaks, kas MAO-A on seotud alkoholi väärkasutamisega, võrdlesin MAOA geeni metüleeritust 
alkoholikasutushäirega meestel (N = 24) ja kontrollgrupil (N = 55). MAOA geeni metüleeritus valgetes 
vererakkudes näitab kaudselt MAO-A aktiivsust ajus. Alkoholikasutushäirega meestel oli keskmine 
metüleeritus kõrgem, kuid ainult siis, kui vaadata eraldi mittesuitsetavaid inimesi (Wilcoxoni p = 0.01, 
paremate tulemuste osakaal = 0.86). Mittesuitsetajatest alkoholikasutushäirega meestel oli metüleeritus 
kõrgem ka geenipiirkonnas CpG10 (p = 0.05, osakaal = 0.80). Suitsetamise ja metüleerituse interaktsioon on 
uudne leid. Kuna mittesuitsetajate valim on väike (N = 5 + 19), peaks neid tulemusi pidama ainult 
esialgseteks. 
Märksõnad: monoamiinoksüdaas A, DNA metülatsioon, alkoholikasutushäire 
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1. Introduction 
1.1. Background information 
Monoamine oxidase (MAO) is an enzyme that catalyzes the breakdown of important neurotransmitters, such 
as serotonin, epinephrine, norepinephrine and dopamine. MAO exists in two forms – A and B. Form A 
(MAO-A) is mainly located in catecholaminergic neurons, form B (MAOA-B) is mainly synthesized in 
serotonergic and histaminergic neurons and astrocytes (as reviewed by Bortolato, Chen & Shih, 2008).  
Studies have shown that both dopamine and norepinephrine play an important role in alcohol dependency 
(Morikawa & Morrisett, 2010; Weinshenker & Schroeder, 2007). Because dopamine and norepinephrine are 
both related to alcohol dependency and because MAO-A plays a role in their metabolism, we could assume 
that the activity of MAO-A in the brain is also related to alcohol dependency.  
One factor that could affect MAO-A brain activity is the methylation of MAOA gene
1
. In a recent study, 
Shumay, Logan, Volkow and Fowler (2012) found that average methylation of the promoter region of 
MAOA gene in white blood cells is correlated to the activity of MAO-A inside the brain (r = –0.61, p < 
0.001).  
Methylation is the addition of methyl groups to the base pairs of DNA, mainly to cytosine in multicellular 
organisms (Klose & Bird, 2006, p. 89, 91). Methyl group itself consists of one carbon atom and three 
hydrogens. Methylation could be one of the mechanisms for regulating gene activity, because it is related to 
gene silencing (Brenet et al, 2011, p. 5–6). 
Considering the information above, we can hypothesize that the methylation state of MAOA gene in white 
blood cells is related to alcohol dependency. In a recent study, this relationship was found in women 
(Philibert, Gunter, Beach, Brody, & Madan, 2008). Philibert and colleagues did not report if methylation was 
higher or lower. However, Zhang et al. (2013) found in a genome wide study that in people with alcohol 
dependency, methylation was lower in most gene regions which were differently methylated. 
Therefore, I am starting from the idea that methylation is lower in people who use alcohol harmfully.  
  
                                                     
1
 In this paper, the symbol “MAO-A” refers to monoamine oxidase A enzyme and the symbol “MAOA” refers to 
monoamine oxidase A gene. This is a guideline of the HUGO Gene Nomenclature Committee (Wain et al., 2002). 
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1.2. Research design and hypotheses 
In this study, I am testing the hypothesis that methylation is lower in people who abuse alcohol. For that 
purpose I am comparing two groups of males – men with or without alcohol use disorders (AUD). 
As I am comparing two groups, it is important that the groups would be similar in terms of other variables 
that can also affect methylation. These variables are gender, age, MAOA genotype and smoking (see 2.2). In 
this data, smoking frequency is not similar in groups. I will therefore use statistical methods to control for 
smoking. Because of that, it is convenient to structure my analysis around two questions: 
1. Is methylation lower in the AUD group? 
2. Is methylation lower in the AUD group, when smoking is controlled for? 
In addition, it would be interesting to know if there has been more stress in the AUD group. This is 
important, because methylation could be related to stress. For example, Domschke et al. (2012, p. 1223) 
found that the occurrence of negative life events in previous 6 or 12 months was associated with decreased 
methylation at two sites of MAOA gene and suggested that methylation could mediate the influence of 
stressful events on mental disorders. Therefore, if the two groups differ both in methylation and stress, it is 
possible that methylation mediates the relationship between stress and alcohol abuse. To explore this 
possibility, I will add a third research question: 
3. Has there been more stress in the AUD group? 
However, the question about stress is not the main focus. Considering the data used for this study, it is not 
possible to clearly show whether mediation exists or not.
2
 Nevertheless, adding this question is still of 
interest, because it can show whether a mediating relationship is possible. 
To explore these three questions, I am analyzing data that has already been collected by the research team of 
Jaanus Harro in cooperation with the National Institute for Health Development in Tallinn. The details of this 
data analysis are discussed in section 2 and results are given in section 3.  
                                                     
2 I considered Kenny’s (2014) suggestions for showing mediation and came to the conclusion that there are three reasons why 
mediation cannot be clearly shown in this study. Firstly, at the moment we do not have longitudinal data for methylation. Only if 
methylation precedes alcohol abuse in time, can it be a mediator. Secondly, another important property of mediation cannot be 
shown: when methylation is controlled for, the effect of stress on alcohol abuse should be weaker or nonexistent. This property 
cannot be shown, because the regression model should have three predictor variables (stress, methylation and smoking), but sample 
size is too low for having three predictors (n  = 24 in the smaller group). Thirdly, because I have a case-control sample for alcohol 
abuse, I do not have a random sample of people with respect to stress. Random sample for stress is necessary to show the effect of 
stress on methylation, and for being able to compare the regression equations used for establishing mediation. 
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1.3. Importance of the study 
First, if people with alcohol use disorders differ in methylation, methylation could become a diagnostic 
marker (as suggested by Zhang et al, 2013, p. 393).  
Second, this study could provide additional knowledge about the role of MAO-A in alcohol abuse in 
humans. I am aware of only one study that has been done on the role of MAOA methylation in alcohol 
dependency (Philibert et al, 2008). There also seems to be a lack of studies looking at the general role of 
methylation in alcohol dependency – Zhang et al. (2013, p. 393) list 5 studies in the introduction of their own 
report. 
Third, this study could hint at the interplay of gene activity (methylation) and environment (stress). To my 
knowledge, there are no studies that have looked at both MAOA methylation and the number of stressful 
events. However, this study is not fully suited for showing a relationship between stress and methylation. 
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2. Method 
2.1. Initial data collection and later data selection 
Sample. Participants were taken from the Estonian sample of European Youth Heart Study (EYHS), which 
was later developed into the Estonian Children Personality Behaviour and Health Study (ECPBHS). This 
study uses the older cohort of EYHS. 37 males who had abused alcohol in their life and 82 males who had 
not abused alcohol were selected for analysis. People were not recruited separately for this study – data 
comes from their blood samples and other measures recorded in the database of ECPBHS. 
Gender. Only male participants were chosen in order to reduce the complexity of analysis (see 2.2. below). 
Measurement waves. In the ECPBHS study, participants were measured three times – in 1998, 2001 and 
2008, when they were approximately 15, 18 and 25 years old. Among other measures, their blood samples 
were obtained. For the purposes of this study, MAOA gene methylation was measured from blood samples 
collected in 1998, 2001 and 2008. Blood samples were put into four plates; two plates were analyzed at one 
time and two plates were analyzed at a later time. 
Choice of data for this study. The quality of methylation data was found to be unclear, because blood 
samples that were analyzed at a later time gave significantly lower results. This suggested that analysis 
conditions may not have been equal. Considering this, as well as considering size limits of this paper, I report 
results only for methylation data obtained from a single plate (plate number four). This plate contains 
methylation data for year 2008 and includes results for 24 males with alcohol use disorder and 55 males 
without the disorder. Therefore, final sample size is smaller (24 + 55) and methylation data is not 
longitudinal as initially planned. 
 
2.2. Control variables 
Besides alcohol abuse, other characteristics can influence methylation. These characteristics are gender, age, 
and smoking frequency, as well as MAOA genotype. Values for these variables are shown in Table 1. 
Gender. Only male participants were chosen to reduce the complexity of study. Females have two X-
chromosomes and one of them is inactivated for dosage compensation, partly by methylation (Wutz, 2011). 
MAOA gene is localized on the X-chromosome (Bortolato et al, 2008). Therefore, one copy of MAOA gene is 
silenced in females. In addition, MAOA methylation could differ in males and females (Domschke et al, 
2012). These are the reasons why including females would make the analysis more complex. 
Age. It is important to control for age because MAO-A activity may change during lifespan (as cited by 
Shumay & Fowler, 2010, p. 326). This means that methylation could also change in time. In this study, age is 
automatically controlled for because participants were measured at similar ages. 
TAMM 
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Smoking frequency. Smoking can influence MAOA methylation (Philibert et al, 2009). The percentage of 
people who smoked daily or almost daily is larger in the AUD group (56.5% vs. 37.8%), and the percentage 
of nonsmokers is lower (21.7% vs. 42.2%). Thus, the sampled groups differ in smoking. 
MAOA genotype. The number of repetitive DNA sequences in the promoter region of MAOA gene (“MAOA 
genotype”) might also influence MAO-A activity, as summarized by Shumay et al. (2012, p. 1151). But the 
effect of genotype may not be very important, because Shumay et al. did not find a relationship between 
MAOA genotype and MAO-A brain activity. Moreover, the distribution of genotypes is similar between two 
groups, so this influence is sufficiently controlled for. 
In conclusion, participants are similar in most of the important characteristics (age, sex, MAOA 
genotype), but they differ in smoking frequency which needs to be controlled for. 
 
 
Table 1 
Values of control variables for AUD group and control group 
Control variable AUD group Control group 
Number of males, n (%) 24 (100.0) 55 (100.0) 
Approximate age in 2008 25 25 
Smoking frequency in 2008, n (%) 
  never 5 (21.7) 19 (42.2) 
few times 2 (8.7) 4 (8.9) 
1-2 times per month 2 (8.7) 2 (4.4) 
1-2 times per week 1 (4.4) 3 (6.7) 
almost every day 2 (8.7) 3 (6.7) 
every day 11 (47.8) 14 (31.1) 
MAOA VNTR, n (%) 
  3 11 (45.8) 23 (41.1) 
4 11 (45.8) 33 (58.9) 
5 2 (8.3) 0 (0.0) 
Note. AUD group = group where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008; MAOA VNTR = number 
of repetitive sequences in MAOA promoter region. Smoking frequency data is not available for 11 people in the control group.  
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2.3. Measures and data screening 
Lifetime incidence of alcohol use disorder (AUD). Mini International Neuropsychiatric Interview (MINI) 
was conducted in 2008 by experienced clinical psychologist to assess whether participants had suffered from 
alcohol use disorder in their life (for references, see Laas et al., 2014, p. 2). 
Stressful life events. Participants reported the number of stressful events in 1998, 2001 and 2008. They were 
given a list of stressful events and they had to indicate which of these they had experienced. Events included 
parental death, parental alcoholism, emotional abuse and other adverse occurrences (see Kiive et al., 2014, p. 
22). For each person, the number of events was counted. This served as a measure of stress. However, the 
lists varied across years. They were not made comparable, because stress is not the main focus of this study. 
Methylation. Methylation was measured in Würzburg University with bisulfite-method (see Appendix 1). 
Methylation was measured at 12 DNA sites that are located in the promoter region of MAOA gene (see 
Shumay et al., 2012, p. 1152). These sites are called “CpG sites”3 and denoted as CpG1, CpG2, ..., CpG12. 
Numbering of these sites is shifted relative to the study of Shumay and colleagues – CpG1 in this study 
corresponds to CpG3 in Shumay study, CpG2 corresponds to CpG4, etc. In this article, I report results only 
for CpG9, CpG10 and average methylation across all twelve CpG sites (“CpGmean”), because these 
variables were shown to have highest correlations with MAO-A brain activity. For CpG9, Spearman r  was –
0.62, for CpG10, Spearman r was –0.62, and for CpGmean, Pearson r was –0.61 (Shumay et al., 2012, p. 
1153–1154). Methylation is expressed as “the proportion of methylated DNA molecules” (see Table 2). 
Data screening. I analyzed descriptive statistics, missing values, outliers and shape and found data to be 
suitable. Most of the methylation and stress variables were not normally distributed (see Appendix 2). 
 
Table 2 
Summary of the measures used in this study 
Measure Possible values Description 
Lifetime incidence of 
alcohol use disorder 
1, 0 Presence of alcohol use disorder during life (1 = yes, 0 = no), assessed 
with MINI interview in 2008. 
Stressful life events 0, 1, 2, … Number of stressful life events, self-reported in 1998, 2001 and 2008. 
Participants were given a list of adverse events and had to indicate 
which of these they had experienced. 
Methylation 0 … 1 Methylation of MAOA promoter region, measured at 12 DNA sites 
("CpG sites"). Takes values between 0 and 1 which show the proportion 
of methylated DNA molecules at a given site. For example, if CpG9 = 
0.33, then 33% of DNA molecules were methylated at site CpG9. This 
study reports the results for CpG9, CpG10 and average methylation 
across all 12 CpG sites (CpGmean). 
                                                     
3
 Only the cytosines (C) that are followed by guanine (G) can be methylated. For this reason, methylated sites are called 
“CpG” sites, where p refers to the phospodiester chemical bond which connects the C and G base pairs. (Lodish et al., 
2013, p. 18, 296, 327; Klose & Bird, 2006) 
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2.4. Statistical tests 
Choice of tests. I considered both parametric and nonparametric tests and came to the conclusion that 
nonparametric tests are the safest choice (see Appendix 3 for details). For the simple two-group comparisons 
(research questions 1 and 3), I use Wilcoxon rank-sum test
4
. For comparing methylation proportions of two 
groups while controlling for smoking (research question 2), I use logistic regression. When methylation and 
smoking are in the same regression model, it is possible to find the effect of methylation while the values of 
smoking are held constant. In addition, even though my hypotheses are directional, I will only calculate two-
sided P-values. This assures that important results are not missed, when an opposite difference is found 
(Agresti & Franklin, 2014, p. 418). 
Statistical software. I performed all statistical tests with the free version of SAS (SAS Institute, 2014). 
Effect sizes. American Psychological Association recommends the reporting of effect sizes. Effect sizes give 
additional information. For example, when effects are large but P-values are nonsignificant, further research 
with higher power may be warranted. (Fritz, Morris, & Richler, 2012, p. 1) For Wilcoxon rank-sum test, I 
report the rank correlation coefficient r. For logistic regression, I mainly report the probability of belonging 
to the AUD group at minimum and maximum methylation values. When reporting these effect sizes, I will 
describe their conventional interpretation. However, these are only a guideline – whether an effect size 
should be considered “small” or “large” depends on the research goals (Fritz et al., 2012, p. 15). For 
example, Rosnow and Rosenthal (as cited by Fritz et al., 2012) say that if a new procedure has a small effect 
size for preventing heart attacks, it could still save lives. 
Statistical power. It is possible that the results of this study are not statistically significant, even though a 
significant difference exists in the population. Therefore, power calculations are useful for interpreting the 
study’s results. Unfortunately, power calculations for Wilcoxon rank-sum test (Zhao, Rahardja, & Qu, 2008) 
and logistic regression (Agresti, 2007, p. 160) seem complicated and I found no free and simple software for 
that purpose. However, power calculations for t-test are simpler. In this study, where sample sizes are 24 and 
55, power of independent samples t-test would be approximately 60% for detecting medium effect size 
(Aron, Coups, & Aron, 2013a, p. 294, 299). This suggests that power may be less than optimal in this study, 
even though I did not do precise calculations. 
Multiple comparisons. If one would perform many statistical tests at the same time for variables that are 
independent of each other, it is possible that one of these tests turns out significant just by chance (Bender & 
Lange, 2001). In this study, I am performing three tests at the same time (comparing CpG9, CpG10 and 
average methylation). As the number of tests is small and these variables are correlated (Spearman r is 
between 0.35 and 0.67, p < 0.01), adjusting for multiple comparisons does not seem a problem. 
                                                     
4 Wilcoxon rank-sum test is equivalent to Mann-Whitney U test (Agresti & Franklin, 2014, p. 730). 
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3. Results 
3.1. Is methylation lower in the AUD group? 
Nonparametric test P-values. According to Wilcoxon rank-sum test, groups did not differ in methylation. 
This applied to sites CpG9 and CpG10, as well as average methylation. P-values for these three variables 
were higher than 0.25. Results are listed in Table 3. 
Nonparametric test effect sizes. Even when the differences are not statistically significant, it is useful to 
check effect sizes (see 2.4). For CpG9 and CpG10, effect size r was 0.11 and 0.13, respectively. For average 
methylation, r = 0.05. According to McGrath and Meyer (2006, p. 390), r = 0.10 could represent small effect 
size and r = 0.24 medium effect size. Therefore, effect sizes for CpG9 and CpG10 can be considered small. 
Additional calculations. When extreme outliers (z > 2.5) were deleted for each of the methylation variables, 
the pattern of results did not change. This was expected, because Wilcoxon test is less sensitive to outliers 
(Fay & Proschan, 2010, p. 25). Scatterplots of methylation proportions (Appendix 4), as well as means and 
medians (Appendix 2) also confirmed that one group did not have clearly higher methylation proportions 
than the other group. However, medians were slightly higher in the AUD group (CpG9: 0.16 vs. 0.14; 
CpG10: 0.16 vs. 0.15; CpGmean: 0.22 vs. 0.21). 
 
Table 3 
Comparison of methylation proportions between AUD group and control group by Wilcoxon rank-sum test 
Variable 
Mean rank 
in AUD 
group 
Mean rank 
in control 
group 
N  
AUD 
N  
control 
Z 
asymp 
p 
asymp 
Effect size 
(r) 
CpG9 43.85 38.32 24 55 0.98 0.33 0.11 
CpG10 44.48 38.05 24 55 1.14 0.25 0.13 
CpGmean 41.67 39.27 24 55 0.42 0.67 0.05 
Note. CpG9 = methylation at site CpG9 in year 2008; CpGmean = average methylation across all CpG sites in year 2008; AUD 
group = group where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008; Z asymp. = z-test statistic for large-
sample Wilcoxon test; p asymp = p-value for Wilcoxon rank-sum test based on the z-statistic; effect size (r) = correlation between 
alcohol abuse and methylation (when observations are ranked), a measure of effect size. 
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3.2. Is methylation lower in the AUD group, when smoking is controlled for? 
Controlling for smoking with logistic regression. I performed logistic regression separately for each of the 
three methylation variables. Firstly, I looked at models where the predicted variable is lifetime incidence of 
alcohol use disorder (1 = yes, 0 = no) and predictor variable is methylation. Secondly, I added smoking 
frequency to the model. This shows whether controlling for smoking improves the predictive power of 
methylation. I also combined the six categories of smoking variable into three, so that frequencies of people 
would be higher and results more trustable. The three new categories can be labelled as: 0 = nonsmokers, 1 = 
intermediate smokers, 2 = daily smokers. After fitting the models, I looked at P-values, effect sizes and 
model fit statistics. I also checked for the influence of outliers or missing values. See Appendix 5 for details. 
Initial results for logistic regression. When smoking was controlled for, methylation at gene sites CpG9 
and CpG10 tended to predict alcohol abuse (p = 0.14 for both sites). When interaction with smoking was 
controlled for, average methylation predicted alcohol abuse (p = 0.02). Effect of average methylation was 
largest for nonsmokers – if average methylation changed from lower quartile to upper quartile value, 
probability of alcohol abuse in the sample increased 26%. The effect was smaller for intermediate smokers 
(change in probability = 16%) and even smaller and opposite for daily smokers (change = –11%). This 
suggested that there was an interaction between methylation and smoking and that methylation tended  to be 
higher in the AUD group. In addition, even though results for CpG9 and CpG10 were affected by outliers or 
missing values, the model for average methylation seemed robust to outliers. See Appendix 5. 
The inadequacy of logistic regression results. As mentioned above, the effect of average methylation was 
large in the nonsmokers’ group. However, the number of people with AUD was not large in that group (N = 
5). Only later it occurred to me that this small group could be responsible for all of the findings. In order to 
test this, I deleted 3 people (who use alcohol harmfully) from the nonsmokers’ group. After that, P-values for 
CpG9, CpG10 and average methylation turned out statistically insignificant – they were not significant (or 
near significance) in models where methylation was the only predictor, where smoking was included, or 
where interaction with smoking was included. Additional evidence also suggested that these three people in 
the nonsmokers’ group had large influence.5 I did not detect these three people in the outlier analysis, 
because their z-scores were not high and they were not clearly visible in the diagnostic plots provided by 
statistical software. This suggested two things. First, the difference between AUD group and control group 
was only seen for nonsmokers (but not for intermediate smokers or daily smokers, as the interaction model 
suggested). Second, this difference was strong, but it was less trustable due to very small sample size. Figure 
1 shows methylation proportions for nonsmokers. 
                                                     
5
 In addition, I recategorized the smoking variable into two categories (daily smokers vs. all others), so that the number 
of people in both categories is larger. The scores of these 3 people still determined the effects of methylation in 
regression models that include smoking. I also looked at the intermediate smokers’ group and daily smokers’ group 
separately. If the interaction model (that showed a large effect for methylation) would be correct, the effect of 
methylation on alcohol abuse should be visible in these groups. I found no effect, which again suggests that the effect of 
the nonsmokers’ group determined the models. 
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Association between methylation and alcohol abuse in the nonsmokers’ group. To quantify the 
difference between AUD group and control group in the nonsmokers’ subsample, I performed Wilcoxon 
rank-sum test. Because sample size is small, I chose the exact-distribution version of this test (Agresti & 
Franklin, 2014, p. 731). According to Wilcoxon test, methylation was higher in the AUD group. This applied 
to site CpG10 (p = 0.05) and average methylation (p = 0.01). In order to assess effect size, I calculated the 
proportion of better responses for AUD group (Agresti & Franklin, 2014, p. 735). With small sample, this 
measure of effect size could be more appropriate than correlation. Proportion of better responses in the AUD 
group was 0.86 for average methylation. In other words, when the observations of AUD group and control 
group were paired in all possible combinations, AUD group had a higher result in 86% of the pairs. If there 
would have been no effect, this percentage would have been 50. This means that effect size for both average 
methylation (0.86) and CpG10 (0.80) was considerable. Results are shown in Table 4.  
  
Table 4 
Comparison of methylation proportions between AUD group and control group when only nonsmokers are 
included in the sample 
Variable 
Mean rank 
in AUD 
group 
Mean rank 
in control 
group 
N  
AUD 
N  
control 
p 
exact 
Effect size  
(Proportion of 
better responses) 
CpG9 15.40 11.74 5 19 0.32 0.66 
CpG10 18.00 11.05 5 19 0.05 0.80 
CpGmean 19.40 10.68 5 19 0.01 0.86 
Note. CpG9 = methylation at site CpG9 in year 2008; CpGmean = average methylation across all observed gene sites in 2008; AUD 
group = group where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008; p exact = p-value for Wilcoxon rank-
sum test based on the exact distribution. 
 
Figure 1. Methylation proportions for nonsmokers in the AUD group (red) and control group (blue). X-axis shows the 
identification number of each person. Y-axis shows the average methylation proportion calculated across observed gene 
sites. AUD group = the group of people where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008. 
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3.3. Has there been more stress in the AUD group? 
Nonparametric tests. According to Wilcoxon rank-sum test, the number of stressful life events recorded in 
2001 was higher in the AUD group compared to the control group (p = 0.03, r = 0.25). Effect size r could be 
considered medium. However, there were no significant differences in the number of stressful events 
recorded in 1998 and 2008. Results are listed in Table 5. 
Checks for outliers. If outliers (z > 2.5) were deleted for each of the stress variables (two outliers for stress 
1998 and 2001, one outlier for stress 2008), the pattern of results did not change. However, P-value for stress 
2001 was somewhat lower (p = 0.01). 
Additional calculations. In order to better interpret the results, I made the following calculation (as 
described by Agresti & Franklin, 2014, p. 466). The number of people who had experienced at least 3 
stressful life events by year 2001 was 31.5% higher in the AUD group compared to the control group. 95% 
confidence limits of this difference were [8.7%, 54.4%]. This comes from the fact that 14 people out of 24 
(58.3%) in the AUD group had experienced at least 3 stressful events, compared to 15 people out of 56 
(26.8%) in the control group. 
 
Table 5 
Comparing the number of stressful life events between AUD group and control group by Wilcoxon rank-sum 
test 
Variable 
Mean rank 
in AUD 
group 
Mean rank 
in control 
group 
N  
AUD 
N  
control 
Z 
asymp 
p 
asymp 
Effect size 
(r) 
Stress 1998 44.19 38.92 24 56 0.95 0.34 0.11 
Stress 2001 48.13 35.89 23 55 2.22 0.03 0.25 
Stress 2008 40.63 40.45 24 56 0.03 0.98 0.00 
Note. Stress 1998 = number of stressful life events as reported in 1998; AUD group = group where lifetime incidence of alcohol use 
disorder (AUD) was diagnosed in 2008; Z asymp. = z-test statistic for large-sample Wilcoxon test; p asymp = p-value for Wilcoxon 
rank-sum test based on the z-statistic; effect size (r) = correlation between alcohol abuse and stress (when observations are ranked), a 
measure of effect size. 
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4. Discussion 
4.1. Limitations of this study 
First, sample size is small (N = 24 + 55), especially when nonsmokers are analysed separately (N = 5 + 19). 
Therefore, when all people are analyzed together, the statistical power may not be optimal for detecting a 
difference. When only nonsmokers are analyzed, the sample may not be representative of nonsmokers with 
alcohol use disorders. 
Second, incidence of alcohol use disorder is assumed to be a binary variable – a person can either have a 
disorder or not. But there could be different degrees of alcohol abuse. For example, among those people who 
are not diagnosed with alcohol use disorder, there could be many who use alcohol in an unhealthy way, but 
who do not reach the threshold of diagnosis. If this is so, then using a discrete measure (yes/no) can lead to 
loss of information – people who use alcohol in a rather harmful way may be classified in the same category 
with people who do not use it at all (Markon, Chmielewski, & Miller, 2011, p. 869; Aron et al., 2013a, p. 
398). This could be true in the current study, as alcohol use in the control group is high (48.2% of people in 
the control group used alcohol every week). 
Third, this study supposes that the methylation of MAOA gene in white blood cells is an indicator for the 
activity of MAO-A inside the brain. Indeed, Shumay et al. (2012) found a correlation in the order of 0.60. 
According to one interpretation, r = 0.60 means that 36% of the variability in MAO-A brain activity can be 
explained by methylation (Agresti & Franklin, 2014, p. 594). This means that the two groups could differ in 
monoamine oxidase brain activity, but this difference may not be reflected in methylation. 
Fourth, groups are not equal in smoking, which can also affect methylation. Smoking can be statistically 
controlled, but statistical control presupposes that the effect of each smoking frequency is similar to different 
people. In reality, it is probably not. This can make the results less precise. Nevertheless, statistical control 
might often be the best choice. It may be hard to get a sample of people who use alcohol harmfully but who 
do not smoke, because alcohol abuse and smoking often co-occur (as cited by Engle, McIntosh, & Drenan, 
2014, p. 13). In addition, groups were not randomly assigned. But this is inevitable for case-control studies. 
Nevertheless, this study also has strengths. The groups are equal in several important control variables, the 
sample size probably allows to detect large effect sizes, methylation is considerably correlated to MAO-A 
brain activity, and results can be generalized to humans (this would be harder if it was an animal study). 
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4.2. Were the hypotheses confirmed? 
First, this study shows that methylation could be higher in the AUD group, but only when nonsmokers are 
analyzed separately. Is this result reliable? Very small sample size means it is not. Regardless of the 
significant P-value, AUD group had only five people which means that findings could be due to chance. On 
the other hand, there are reasons for assuming that methylation is associated with alcohol abuse in the 
nonsmokers’ group, but not in the smokers’ group (see 4.5). Therefore, this study suggests that methylation 
could be higher, even though evidence is weak. Future studies with larger samples are needed.  
Second, no differences between AUD group and control group were found in the overall sample. More 
precisely, there was no difference in the smokers’ group. Can it be concluded that there is no such difference 
in the population? Considering the limitations of this study (4.1), the answer is “probably not”. However, 
because sample size could be sufficient for detecting large effect sizes, this study suggest that there may not 
be a large difference in population between these two groups. 
Third, groups differ in the number of stressful life events. It is thus possible that methylation mediates the 
relationship between stress and alcohol abuse, although this relationship might apply only to nonsmokers. In 
addition, the difference between groups was found only for the number of stressful events reported in 2001, 
but not in 1998 or 2008. The reason for this is unclear, because the lists of stressful events varied across 
years. I did not investigate this more, as the question of stress was not the main focus of the study. 
 
4.3. Benefits of studying MAOA methylation 
In section 1.3, I listed three potential benefits of studying methylation. Does this study confirm the benefits?  
On one hand, this study does not support the idea that methylation could become a diagnostic marker for 
alcohol abuse. If methylation would be used to assess the risk of alcohol dependency, it would need to 
clearly differentiate people who abuse alcohol from people who do not. As methylation can be influenced by 
smoking, it is not a reliable marker, especially because alcohol use is often accompanied by smoking (as 
cited by Engle, McIntosh, & Drenan, 2014, p. 13).  
On the other hand, this study supports the ideas that MAO-A could play a role in alcohol abuse and that 
stress might mediate this relationship. Therefore, the results suggest that studying methylation can be useful, 
even though methylation might not become a diagnostic marker. 
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4.4. Relationship between methylation and alcohol abuse 
What could be the reason for higher methylation in the AUD group? And more generally, how could 
methylation influence alcohol abuse? 
A simple hypothesis might look like this. It is believed that ethanol stimulates dopamine neurons in ventral 
tegmental area, which leads to the release of dopamine in nucleus accumbens. This release could underlie the 
rewarding and reinforcing effects of alcohol (Morikawa & Morrisett, 2010). On the other hand, higher 
methylation is associated with lower MAO-A brain activity (Shumay et al., 2012). Thus, if MAO-A activity 
is lower, breakdown of dopamine might be slower and people might be more sensitive to the rewarding and 
reinforcing effects of alcohol.  
In addition, norepinephrine could stimulate dopamine release in nucleus accumbens through direct and 
indirect pathways. (Weinshenker & Schroeder, 2007, p. 1439 –1440) If MAO-A activity is lower, the 
concentration of norepinephrine may be higher. Higher concentration of norepinephrine could lead to higher 
concentration of dopamine, which would again make people more sensitive to ethanol. 
This simple hypothesis can hold even if the actual mechanisms of ethanol on dopamine are complex (the 
complexity was stressed by Wu, Gao & Taylor, 2014, p. 311–312). For example, Morikawa and Morrisett 
(2010) describe how ethanol can influence dopamine neurons directly and indirectly. In direct influence, 
ethanol affects the intrinsic firing rhythm of dopamine neurons through various ion channels. In indirect 
influence, ethanol influences other neurotransmitters, which in turn influence dopamine release. But 
regardless of how dopamine is released, MAO-A could still influence its breakdown. 
On the other hand, this hypothesis may be too simple, because MAO-A is not the only enzyme involved in 
the breakdown of dopamine and norepinephrine (Bortolato et al., 2008, p. 1528–1529). In addition, MAO-A 
is located inside neurons as well as glial cells (Youdim, Edmondson & Tipton, 2006). This means that there 
could be different pathways by which MAO-A influences dopamine. Moreover, various other factors can 
influence alcohol use. For example, Zhang et al. (2013, p. 395) found that 1710 gene sites (not genes) were 
differently methylated in people with alcohol dependency. And these are only biological factors. There could 
also be psychological and social factors. 
Also, this hypothesis presupposes that methylation increases the risk of alcohol abuse. But alcohol use itself 
(like smoking) could affect methylation. This study does not give information about the direction of 
influence, because data is not longitudinal. 
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4.5. Interaction between smoking and methylation 
The idea that methylation is associated with alcohol abuse, but only for nonsmokers, seems to fit with the 
results of a recent study. Engle, McIntosh and Drenan (2015, p. 17) found that low concentrations of nicotine 
and ethanol, when applied together, evoked electrical potentials from dopamine neurons, but these 
substances did not have such effect when applied separately in their small concentrations. This means that 
the overall effect of nicotine and ethanol can be much stronger when these substances are used together. In 
fact, authors estimate that just one cigarette and one drink could be enough to induce plastic changes in 
dopamine neurons.  Therefore, even if lower methylation makes people less prone to ethanol addiction (see 
4.4), it may not be enough to protect them from the co-exposure of these two substances. When nicotine and 
ethanol are used together, the effect may be so strong that it overrides the effect of methylation. 
  
4.6. Ideas for future studies 
There are various ways for studying the role of MAO-A in alcohol abuse. For example: 
 A study similar to this one, where sample size is larger, alcohol use frequency in the control group is 
smaller, and methylation data is longitudinal (which is possible in the ECPBHS sample). 
 A neuroimaging study with humans where the activity of MAO-A is measured directly in the brain 
for cases and controls. The measurement protocol could be similar to Shumay et al. (2012). In 
addition, it might be interesting to do an experiment where the brain activity of MAO-A is measured 
before and after ethanol consumption. These studies are expensive, but can give strong evidence. 
 A biological study that measures the effect of MAO-A inhibitors on the electrical potentials evoked 
from dopamine neurons. The protocol could be similar to Engle et al. (2015).  
Biological mechanisms of alcohol abuse could also be studied more generally with new technologies. For 
example, it would be interesting to analyze microRNA-s obtained from human blood. MicroRNA-s are 
molecules that are suggested to be master regulators of protein expression and they could be novel diagnostic 
biomarkers for human disease (as referenced by Gorini, Nunez, & Mayfield, 2013). Indeed, Gorini et al. 
(2013) found that microRNA levels were different in ethanol dependent mice. 
 
4.7. Conclusion 
In summary, this study shows that methylation could be related to alcohol abuse, but only in the nonsmokers’ 
group – perhaps a novel finding. It also leaves open the possibility that, for nonsmokers, methylation 
mediates the relationship between stress and alcohol abuse. However, due to small sample size and other 
limitations, these findings should be considered as initial and in need of replication.  
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Appendices 
Appendix 1. How was methylation measured? 
Methylation data was obtained similarly to Shumay and colleagues (2012, p. 1156). The research team led by 
Shumay used the following steps. 
1. DNA was isolated from white blood cells in venous blood.  
2. Isolated DNA was treated with a chemical called sodium bisulfite, which converts unmethylated 
cytosines to uracil. See Figure 2. 
3. Polymerase chain reaction (PCR) was carried out with bisulfite-treated DNA. PCR enables to “take 
out” the region of interest from the DNA so that this region can be further analysed. When PCR is 
complete, researchers have a collection of DNA molecules which contain only the region of interest. 
The region of interest in this study is the promoter region of monoamine oxidase A (MAO-A) gene.  
4. PCR products were incorporated into a circular DNA molecule (plasmid). These circular molecules 
were inserted into bacterial cells. This step is important for getting enough DNA for analysis. Even 
though the PCR reaction “takes out” the region of interest, the number of DNA molecules is too 
small for further study. But when the region of interest is inserted into bacteria, it is multiplied. 
When bacteria grow and divide, they also replicate the DNA that is inserted into them. 
5. As a final step, MAOA DNA was extracted from bacterial cells and its sequence was determined in 
order to know which gene sites were methylated. 
 
 
 
Figure 2. When DNA is treated with sodium bisulfite, the chemical converts unmethylated cytosines (C) into 
uracil (U). Later, when the DNA sequence is determined, the number of uracils indicates the number of 
unmethylated sites. Figure is adapted from Wikipedia (2007).  
Treatment with sodium bisulfite 
DNA sequence 
---ACTCCACGG---TCCATCGCT--- 
---TGAGGTGCC---AGGTAGCGA--- 
m 
m 
---AUTUUAUGG---TUUATCGUT--- 
 
---TGAGGTGUU---AGGTAGCGA--- 
 
+ 
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Appendix 2. Data screening, descriptive statistics and normality tests 
Data screening procedure. To see whether data is suitable for analysis, I used the following procedure, 
which I adapted from one statistics textbook (Aron, Coups & Aron, 2013b, p. 19–23): 
 Data table – are there any unusual observations or unusual patterns visible in the data table? 
 Descriptive statistics – are all the minimums, maximums, means and standard deviations within 
theoretically possible boundaries? 
 Missing values – are there many missing values? If so, did they arise randomly? 
 Outliers – do some people have extremely high scores (absolute value of z-score > 3 or > 2.5)? 
 Normal distributions – which of the variables are approximately normally distributed? 
 Shape – which of the variables have approximately the same shape? 
Descriptive statistics. In general, all descriptive statistics were in theoretically possible boundaries and none 
of them seemed extreme at first glance. Descriptive statistics are listed in Table 6.  
Missing values. The number of missing values seemed acceptable too. In the AUD group, there were no 
missing values in the main methylation variables and no more than 2 missing values in each of the other 
variables. In control group, there was only 1 missing value in each of the main methylation variables and no 
more than 2 missing values in the each of the other variables. Smoking frequency variable was the only 
exception – there were 11 missing values in the control group. There did not seem to be a systematic reason 
for this, because these people reported their alcohol frequency (they did not choose to “hide it”). 
Outliers. There were 7 outliers in the three main methylation variables (z  > 2.5), 5 in the control group. 
These outliers seemed to be randomly dispersed over the data table. However, one person had 8 extreme 
observations across all methylation variables. It is unlikely to be measurement error, because all blood 
samples were analyzed together. In addition, if methylation proportions in the population were normally 
distributed, the probability of having outliers (defined by z > 2.5 or z < –2.5) would be approximately 1.2%. 
As the total sample size was 79, there should have been about 1 outlier in the sample (0.012*79). This 
suggested, in addition to other evidence below, that observations in the population may not be normally 
distributed. 
Normal distributions. According to Shapiro-Wilk test, none of the variables were normally distributed in 
both groups. Focusing on methylation variables, quantile-quantile plots and histograms (not shown) 
confirmed that methylation was not normally distributed; the reason seemed to be both in skewness and 
kurtosis (see table 7). 
Could the data be corrected to make it normally distributed? If six people were deleted from the dataset 
who had extreme observations (z > 2.5 or z < –2.5), all of the main methylation variables could be considered 
normally distributed. However, deletions did not seem good for two reasons. First, deletions would have 
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meant a considerable loss of data (about 7%). Second, it is likely that methylation variables are not normally 
distributed in the population, because methylation can take only positive values between 0 and 1 and the 
average for most gene sites is not around 0.5 – both in this data and in the data of Shumay et al. (2012, p. 
1157). This can result in skew due to restricted range of values on one side of the mean. Data transformation 
did not seem good either. First, it would have distorted the original data units and made the results harder to 
interpret. Second, logarithm and square-root transformations did not result in the normality for all variables 
of interest. 
Shape. None of the variables had similar shape in terms of skewness, except for smoking. 
 
Table 6 
Descriptive statistics for control variables and comparison variables 
Variable Possible values Mean Std Dev Min Max Median 
Lower 
Quartile 
Upper 
Quartile N 
N 
Miss 
AUD group 
          
Smoking_2008 1, 2, 3, 4, 5, 6 4.13 2.14 1 6 5 2 6 23 1 
Stress_1998 0, 1, 2, … 1.83 1.24 0 4 2 1 3 24 0 
Stress_2001 0, 1, 2, … 3.00 2.17 0 7 3 1 5 23 1 
Stress_2008 0, 1, 2, … 3.92 2.45 0 9 4 2 6 24 0 
MAOA_VNTR 2, 3, 3.5, 4, 5 3.63 0.65 3 5 4 3 4 24 0 
CpG9 0 … 1 0.16 0.07 0.07 0.40 0.16 0.11 0.18 24 0 
CpG10 0 … 1 0.18 0.07 0.08 0.35 0.16 0.14 0.22 24 0 
CpGmean 0 … 1 0.22 0.04 0.17 0.35 0.22 0.19 0.24 24 0 
Control group 
          
Smoking_2008 1, 2, 3, 4, 5, 6 3.20 2.23 1 6 2 1 6 45 11 
Stress_1998 0, 1, 2, … 1.57 1.29 0 5 1 1 2 56 0 
Stress_2001 0, 1, 2, … 1.80 1.65 0 6 1 1 3 55 1 
Stress_2008 0, 1, 2, … 3.98 2.71 0 11 4 2 6 56 0 
MAOA_VNTR 2, 3, 3.5, 4, 5 3.59 0.50 3 4 4 3 4 56 0 
CpG9 0 … 1 0.14 0.04 0.05 0.26 0.14 0.11 0.16 55 1 
CpG10 0 … 1 0.16 0.06 0.05 0.44 0.15 0.13 0.18 55 1 
CpGmean 0 … 1 0.21 0.03 0.16 0.30 0.21 0.19 0.24 55 1 
Note. AUD group = group where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008; smoking_2008 = smoking 
frequency in last 12 months in 2008 (1 = never; 2 = few times; 3 = one or two times per month; 4 = one or two times per week; 5 = 
almost every day; 6 = every day); stress_1998 = number of stressful life events reported in 1998; MAOA_VNTR = number of 
repetitive sequences in the promoter region of MAOA gene; CpG9 = methylation at site CpG9 in year 2008; CpGmean = average 
methylation across all CpG sites in year 2008; Std Dev = standard deviation; min = minimum value; N miss = number of missing 
values. 
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Table 7 
Shape characteristics for control variables and comparison variables 
Variable Skew Kurt 
SE 
skew 
Z 
skew 
SE 
kurt Z kurt 
Shapiro-
Wilk 
AUD group 
       
Smoking_2008 -0.52 -1.57 0.48 -1.08 0.93 -1.68 <0.0001 
Stress_1998 0.19 -1.16 0.47 0.41 0.92 -1.26 0.01 
Stress_2001 0.35 -1.13 0.48 0.72 0.93 -1.20 0.02 
Stress_2008 0.42 -0.52 0.47 0.88 0.92 -0.56 0.27 
MAOA_VNTR 0.54 -0.52 0.47 1.15 0.92 -0.57 <0.0001 
CpG9 1.86 6.00 0.47 3.94 0.92 6.54 0.00 
CpG10 0.98 0.46 0.47 2.07 0.92 0.50 0.04 
CpGmean 1.15 1.35 0.47 2.44 0.92 1.48 0.04 
Control group 
       
Smoking_2008 0.25 -1.80 0.35 0.71 0.69 -2.60 <0.0001 
Stress_1998 0.81 0.34 0.32 2.53 0.63 0.54 0.00 
Stress_2001 0.85 -0.13 0.32 2.63 0.63 -0.20 <0.0001 
Stress_2008 0.64 -0.03 0.32 2.01 0.63 -0.05 0.01 
MAOA_VNTR -0.37 -1.93 0.32 -1.17 0.63 -3.07 <0.0001 
CpG9 0.40 0.52 0.32 1.24 0.63 0.82 0.32 
CpG10 1.96 6.29 0.32 6.08 0.63 9.93 <0.0001 
CpGmean 0.29 -0.05 0.32 0.91 0.63 -0.08 0.43 
Note. Descriptions for variables are given in the previous table. Skew = skewness; kurt = kurtosis; SE skew = standard error of 
skewness; Z skew = z-score for obtaining a sample with such skewness from a population where skewness is 0; Shapiro-Wilk = P-
value for Shapiro-Wilk normality test. 
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Appendix 3. Statistical tests considered for this research project 
 
Table 8 
Statistical tests considered for this research project: tests are grouped according to research questions 
Research question Statistical test Assumptions Assumptions fulfilled? 
1. Is methylation 
lower in the AUD 
group? Has there been 
more stress in the 
AUD group? 
1.1. Wilcoxon 
rank-sum test 
(1) Response variable is measured at 
least on ordinal scale;  
(2) independent random samples. 
(Agresti & Franklin, 2014, p. 728) 
YES – Assumption (1) is met. 
Assumption (2) is met, but more weakly 
due to nonrandom sample. 
 1.2. Hodges-
Lehmann estimate 
for the difference 
between medians 
(1) Response variable is measured at 
least on ordinal scale;  
(2) independent random samples; 
(3) population distributions have the 
same shape.  
(Agresti & Franklin, 2014, p. 730) 
NO – Assumption (3) is not met. 
  1.3. Independent 
samples t-test 
(1) Response variable is quantitative;  
(2) independent random samples;  
(3) approximately normal population 
distribution for each group or sample 
size larger than 30 in each group. 
(Agresti & Franklin, 2014, p. 481) 
NO – Assumption (3) is not met. 
Distributions are not normal and sample 
size in the smaller group is 24. 
2. Is methylation 
lower in the AUD 
group, when smoking 
is controlled for? 
2.1. Logistic 
regression 
No assumptions about the distribution, 
variance or relationship between 
predictor variables (Tabachnick & 
Fidell, 2001, p. 517). The response 
variable is a binary category (e.g. 0 vs. 
1), so it does not have to be normally 
distributed (Agresti, 2007, p. 67).  
 
However, it is good if the following 
criteria are met: (1) Logit transform of 
the response variable is linearly related 
to predictors; (2) Absence of outliers – 
cases who are very poorly predicted by 
the model;  (3) Independence of errors 
– all cases are independent; 
(Tabachnick & Fidell, 2001, p. 522-
523); (4) At least 10 observations in 
each predicted category for every 
predictor; (5) Absence of high 
correlations between predictors 
(multicollinearity); (Agresti, 2007, p. 
138).  
YES. 
 
In addition, criteria (3) and (4) are met – 
cases and controls are not matched one-
on-one; and the model can 
accommodate at least 2 predictors 
(methylation and smoking) because 
there are at least 24 people in the 
smaller group. Fulfilment of criteria (2) 
and (5) will be evident from the results. 
Outliers will be seen from the 
diagnostic plots (SAS Institute, 2010b , 
p. 3996) and multicollinearity can be 
detected when the overall P-value for 
the model is small, but individual 
effects are not significant (Agresti, 
2007:139). I will not test linearity (1) 
separately. I assume it is indicated by 
the fit of the model. 
  2.2. General linear 
model 
(ANCOVA) 
(1) Relationship between predictors and 
response variables is linear. 
(2) Residuals are normally distributed 
at all combinations of the predictor 
variables. 
(3) Residuals have the same variance at 
all combinations of the predictor 
variables. 
 (Carey, 2004, p.13–14) 
MAYBE – methylation variables are not 
normally distributed in both groups 
which also means that their residuals are 
not normally distributed at the two 
levels of the grouping variable (1 vs. 0). 
However, I did not test if residuals are 
normally distributed when smoking is 
included in the model, and if they have 
same variance. It would have taken 
considerable time to learn to use general 
linear model (in addition to logistic 
regression). This would have taken 
more time than planned for this project. 
I chose logistic regression, because it 
was safe. 
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Appendix 4. Scatterplots for methylation proportions 
 
 
 
 
Figure 3. Scatterplots of methylation proportions. Y-axis shows the methylation proportions for sites CpG9, CpG10 and 
average methylation. X-axis shows the row number of participants. People in the AUD group are marked with red 
circles. AUD group is the group where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008. 
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Appendix 5. Logistic regression analysis 
Regression models. I performed logistic regression separately for each of the three methylation variables. 
Firstly, I looked at models where the predicted variable is lifetime incidence of AUD (1 = yes, 0 = no) and 
predictor variable is methylation. Secondly, I added smoking frequency to the model. This shows whether 
controlling for smoking improves the predictive power of methylation. Smoking frequency was missing for 
11 people, so I excluded them. I also excluded them from the models that contain methylation as the only 
predictor, so that these models would be comparable to models that contain both methylation and smoking. 
Combining the categories of smoking. In the original data, smoking variable has six categories that 
represent different degrees of smoking. However, the number of people in most of these categories is very 
small (see Table 1). I combined the six categories into three, so that frequencies of people would be higher 
and results more trustable.
6
 The three new categories can be labelled as: 0 = nonsmokers, 1 = intermediate 
smokers, 2 = daily smokers. I treated this new smoking variable as a rank-order variable, having confirmed 
that logistic regression allows rank-order predictors. (Agresti, 2007, p. 118) I also tried other ways of 
categorizing and concluded that the three-category choice is appropriate. 
P-values and regression coefficients for methylation. Methylation did not predict group membership in a 
statistically significant way when smoking was controlled for. However, when compared to simpler models 
that did not contain smoking, P-values for methylation were smaller and standardized regression coefficients 
were larger for both CpG9 and average methylation. This suggested that controlling for smoking improves 
the predictive power of methylation. In addition, P-values for CpG9 and CpG10 were not far from 0.05 level 
of significance (p = 0.14 for both sites). Positive regression coefficients for these sites showed that 
methylation tends to be higher in the AUD group. Table 9 shows these results. 
Effect size for methylation. I calculated the probabilities of belonging to the AUD group at minimum and 
maximum methylation values. The difference between these two probabilities shows effect size. For 
example, if methylation values change from minimum to maximum, but the probability of alcohol use 
disorder changes very little, methylation does not have a large effect. However, because minimums and 
maximums are sensitive to outliers, it is better to use lower quartile (LQ) and upper quartile (UQ). (Agresti, 
2007, p. 121) In this calculation, smoking should be fixed at its ordinary value. I chose “0” (“nonsmokers”) 
for the ordinary value, because nonsmokers are most common in the control group.
7
 When smoking was 
fixed at value 0 and methylation increased from LQ to UQ, the probability of belonging to the AUD group 
increased approximately 6%. For example, at site CpG9, probability increased from 0.15 to 0.21. This effect 
seemed small, but noteworthy, as methylation changed only over the middle 50% range of its values. But 
confidence intervals were wide (see 4.1). Table 10 shows the results. 
                                                     
6 In the original data, smoking has six categories (1 = never; 2 = few times; 3 = one or two times per month; 4 = one or two times per 
week; 5 = almost every day; 6 = every day). I combined these into three (0 = never, 1 = few times, one or two times per month, one or 
two times per week; 2 = almost every day, every day). In this case, frequency of people in each category of both groups is at least 5. 
7 In the control group, 42.2% of people never smoked in 2008. They belong to category “0” in the new smoking variable. In 
comparison, only about 20.0% of people belong to category “1”. I chose control group as the reference point, because people who do 
not use alcohol harmfully are probably much more common the population than people who use alcohol harmfully. 
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Effect size for the whole model. I also calculated effect size measures for regression models which contain 
methylation and smoking. Concordance index c was between 0.63 and 0.66 and Nagelkerke R
2
 was between 
0.06 and 0.08.
8
 However, these measures describe the whole model, not methylation in particular. 
Interactions. There was no interaction between smoking and CpG9 or CpG10. However, smoking interacted 
with average methylation (pinteraction = 0.03, βinteraction = –25.94). In this model, the effect of methylation was 
statistically significant (p = 0.02). The effect was largest for nonsmokers – if average methylation changed 
from lower quartile to upper quartile value, probability of alcohol use disorder in the sample increased 26%. 
Effect was smaller for intermediate smokers (change in probability = 16%) and even smaller and opposite for 
daily smokers (change = –11%). In addition, effect size of the whole model was considerable (c = 0.72, 
R
2
Nagelk. = 0.20). This interaction model is included in Table 9 and shown in Figure 4. 
Checks for outliers and missing values. First, I identified extreme observations by looking at z-scores (z > 
2.5 or z > 2.0). I explored the effect of deleting these observations. Second, I looked at diagnostic plots (SAS 
Institute, 2010b, p. 3996) and identified observations that have large effects on the model. Models for 
average methylation and CpG10 seemed quite immune to outliers, while the model for CpG9 was more 
sensitive and thus less reliable. In addition, results for CpG10 were also less trustworthy. The model that 
contained CpG10 as the only predictor was affected by the exclusion of 11 people for whom the smoking 
values were missing.
9
 
Inadequacy of logistic regression models. As mentioned in section 3.2, all of the logistic regression models 
that contained smoking as a predictor variable were influenced by the deletion of three observations from the 
sample. Therefore, none of these models was reliable. These three observations were not detectable from z-
scores and they did not appear clearly on the diagnostic plots. However, I still presented all the logistic 
regression results to show the analysis that I carried out. The inadequacy of these models could have been 
detected more easily, if I would have used the smoking frequency as a coded categorical variable, in addition 
to using it as a rank-order variable. I can take this into account in future studies. 
  
                                                     
8 I considered the following guidelines for interpreting these effect sizes. Concordance index c = 0.50 means that the predictive 
power of the model is not better than random guessing (Agresti, 2007, p. 144) and Nagelkerke R2 represents the proportion of 
variance explained (Nagelkerke, 1991). In ordinary regression, according to Cohen, R2 = 0.02 could represent small effect size and R2 
= 0.13 could represent medium effect size (as cited in Aron et al, 2013a). However, R2 analogues for logistic regression have been 
criticized (e.g. Menard, 2012, p. 20). 
9 When I calculated the model that contains methylation as the only predictor variable, I excluded the scores of 11 people whose 
smoking values were missing. If these people were not excluded, P-value of CpG10 would be higher (p = 0.21 vs. 0.14). Excluding 
these people did not strongly affect models where CpG9 (0.20 vs. 0.25) or average methylation (0.35 vs. 035) were the only 
predictors. 
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Table 9 
Logistic regression models where methylation is a predictor of alcohol abuse: the effects of methylation as a 
single predictor vs. the effects of methylation when smoking is controlled for 
 
Statistics for methylation 
 
Statistics for the whole model 
Model p β 95% CI β  Std. β   p 
c 
index 
R2 Cox 
& Snell 
R2 
Nagelk. AIC –2LogL 
CpG9 0.25 5.87 [-3.8, 16.69] 0.17  
0.23 0.57 0.02 0.03 88.77 84.77 
CpG9 + S 0.14 8.07 [-2, 19.83] 0.23  
0.07 0.66 0.08 0.11 86.75 80.75 
CpG10 0.13 6.53 [-1.7, 15.39] 0.22  
0.12 0.59 0.04 0.05 87.77 83.77 
CpG10 + S 0.14 6.46 [-1.88, 15.52] 0.22  
0.07 0.65 0.08 0.10 86.90 80.90 
CpGmean 0.35 6.68 [-7.34, 21.13] 0.13  
0.35 0.54 0.01 0.02 89.30 85.30 
CpGmean + S 0.23 8.84 [-5.54, 24.17] 0.18  
0.11 0.63 0.06 0.09 87.74 81.74 
CpGmean + S 
+ CpGmean*S 
0.02 42.81 [11.04, 84.51] 0.85 
 
0.02 0.72 0.14 0.20 83.74 75.74 
Note. Models are written in shorthand form. For example, “CpG9 + S” is a logistic regression model that predicts the lifetime 
incidence of alcohol use disorder (yes/no) using two predictors: methylation at site CpG9 and smoking frequency. All models contain 
intercept, only the last model contains interaction. Statistics for methylation are the following: p = p-value according to Wald test; β 
= regression coefficient; 95% CI β = 95% confidence intervals for β according to likelihood-ratio method; Std. β = standardized 
regression coefficient. Statististics for the whole model: p = p-value according to likelihood-ratio method; c index = concordance 
index; R2 Nagelk. = Nagelkerke’s coefficient of determination; AIC = akaike information criterion, shows how close the fitted values 
tend to be to true expected values (smaller AIC is better); –2logL = maximized value of likelihood function.  
 
 
 
Table 10 
Predicted probabilities of alcohol abuse at small and large methylation values: difference between these 
probabilities reflects the effect size of methylation 
Model 
Smoking 
value 
LQ 
methylation 
UQ 
methylation 
Probability 
at LQ 
Probability 
at UQ 
Change in 
probability 
CpG9 - 0.11 0.16 0.29 0.35 0.06 
CpG9 + S 0 0.11 0.16 0.15 0.21 0.06 
CpG10 - 0.13 0.18 0.29 0.36 0.07 
CpG10 + S 0 0.13 0.18 0.18 0.23 0.05 
CpGmean - 0.19 0.24 0.30 0.37 0.06 
CpGmean + S 0 0.19 0.24 0.17 0.24 0.06 
CpGmean + S + CpGmean*S 0 0.19 0.24 0.05 0.32 0.26 
Note. Smoking value “0” represents nonsmokers; LQ methylation = lower quartile value for methylation in the control group; 
probability at LQ = predicted probability of belonging to the AUD group when smoking is at value 0 and methylation is at lower 
quartile value; change in probability = probability at UQ minus probability at LQ, a measure of effect size; AUD group = the group 
where lifetime incidence of alcohol use disorder (AUD) was diagnosed in 2008. 
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Figure 4. Average methylation predicts alcohol abuse, but its predictive power depends on the frequency of smoking. In 
the figure, the minimum value of methylation is the lower quartile value of the control group; the maximum value is the 
upper quartile value. Definitions: probability of alcohol abuse = probability of belonging to the AUD group; average 
methylation = average methylation proportion across all twelve CpG sites (i.e. average methylation of the studied gene 
region); nonsmokers = people who reported that they never smoked in 2008; intermediate smokers = people who 
reported that they smoked a few times, once or twice per month, or once or twice per week in 2008; daily smokers = 
people who reported that they smoked daily or almost daily in 2008. 
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